BIOHAVEN LTD (BHVN:NYSE)
$15.41 -0.71 (-4.4045%)
Analysed BIOHAVEN LTD (BHVN:NYSE) News Sources
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
10-07-2026
biopharmadive.com
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
20-07-2026
yahoo.com
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
06-08-2026
yahoo.com
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
26-08-2026
yahoo.com
Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal
26-08-2026
biopharmadive.com
Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal
26-08-2026
advfn.com
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout
26-08-2026
stocktwits.com
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
27-08-2026
yahoo.com
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
27-08-2026
pharmaceutical-technology.com
Why Biohaven Stock Was Rocking the Market This Week
28-08-2026
fool.com
What is the current price of BIOHAVEN LTD (BHVN:NYSE)?
The current price of BIOHAVEN LTD (BHVN:NYSE) is $15.41.
BIOHAVEN LTD (BHVN:NYSE) absolute price change since previous trading day?
The absolute price change of BIOHAVEN LTD (BHVN:NYSE) since the previous trading day is $-0.71.
BIOHAVEN LTD (BHVN:NYSE) percentage price change since previous trading day?
The percentage price change of BIOHAVEN LTD (BHVN:NYSE) since the previous trading day is -4.4045%.
What is the most recent average sentiment score for BIOHAVEN LTD (BHVN:NYSE)?
The most recent average sentiment score for BIOHAVEN LTD (BHVN:NYSE) is 88 out of 100.
What is the most recent average sentiment for BIOHAVEN LTD (BHVN:NYSE)?
The most recent sentiment for BIOHAVEN LTD (BHVN:NYSE) is .
SEC-8K** Filing Available For BIOHAVEN LTD (BHVN:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.